BIOMAT Database Logo BIOMAT Database Logo

Possible availability of N-acetylcysteine as an adjunct to cytokine therapy for hepatocellular carcinoma. 1998

S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
Graduate School of Medicine, College of Medical Technology, Kyoto University, 54 Shogoin-Kawara-cho, Sakyo-ku, Kyoto, 606-8397, Japan.

To examine the possibility of immunotherapy for activating liver-associated mononuclear cells (liver MNC) in hepatocellular carcinoma (HCC), we evaluated the cytotoxicity of liver MNC and peripheral blood mononuclear cells (PBMNC) in HCC patients and examined how they can be activated by cytokines and how this activation is modulated by reduction/oxidation. Cytotoxicity of liver MNC but not PBMNC in HCC patients was significantly decreased compared with that of controls, despite no alteration in the subpopulation of liver MNC between the two groups. We next measured intracellular glutathione (GSH), which is required for the enhancement of the cytotoxicity by interleukin-2 (IL-2). Intracellular GSH levels of liver MNC in HCC were significantly lower than that of controls. In vitro administration of N-acetylcysteine (NAC) not only restored intracellular GSH levels but also enhanced the IL-2-stimulated cytotoxicity of liver MNC in HCC patients. This suggests that intracellular GSH of liver MNC in HCC may participate in the modulation of cytotoxicity of liver MNC in vitro and that NAC may be effective as an adjunct to immunotherapy for HCC.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D005978 Glutathione A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. Reduced Glutathione,gamma-L-Glu-L-Cys-Gly,gamma-L-Glutamyl-L-Cysteinylglycine,Glutathione, Reduced,gamma L Glu L Cys Gly,gamma L Glutamyl L Cysteinylglycine

Related Publications

S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
N-Acetylcysteine as an adjunct for refractory ear infections.
December 2007, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.
January 2022, Advances in pharmacological and pharmaceutical sciences,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
Ameliorative Effects Of N-Acetylcysteine As Adjunct Therapy On Symptoms Of Painful Diabetic Neuropathy.
January 2019, Journal of pain research,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication.
February 2019, The Cochrane database of systematic reviews,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
The effects of low dose N-acetylcysteine (NAC) as an adjunct to cardioplegia in coronary artery bypass surgery.
December 2008, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
Peretinoin as an adjuvant therapy for hepatocellular carcinoma.
November 2016, Expert review of gastroenterology & hepatology,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma.
January 1976, The Journal of clinical endocrinology and metabolism,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
MicroRNAs as possible biomarkers for hepatocellular carcinoma.
June 2018, Hepatology research : the official journal of the Japan Society of Hepatology,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
Pelvic lymphnodectomy as an adjunct to the radiation therapy of cervical carcinoma.
December 1967, Clinical obstetrics and gynecology,
S Tsuyuki, and A Yamauchi, and H Nakamura, and K Kinoshita, and T Gomi, and K Tanaka, and T Inamoto, and Y Yamaoka
Carcinoma of the rectum: preoperative radiation therapy as an adjunct to surgery.
January 1974, Diseases of the colon and rectum,
Copied contents to your clipboard!